ProMIS Neurosciences (PMN) News Today → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free PMN Stock Alerts $1.84 -0.16 (-7.98%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 10:37 AM | msn.comPMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024May 14, 2024 | globenewswire.comProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent HighlightsMay 8, 2024 | americanbankingnews.comHead to Head Comparison: ProMIS Neurosciences (NASDAQ:PMN) versus Bullfrog AI (NASDAQ:BFRG)May 1, 2024 | marketbeat.comTrading was temporarily halted for "PMN" at 09:05 AM with a stated reason of "LULD pause." Trading set to resume at 09:05 AM. April 30, 2024 | globenewswire.comProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed AntibodiesApril 17, 2024 | msn.comProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93April 9, 2024 | globenewswire.comProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSApril 4, 2024 | globenewswire.comProMIS Neurosciences to Present in Upcoming Investor Conferences in AprilApril 1, 2024 | globenewswire.comProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsMarch 11, 2024 | globenewswire.comProMIS Neurosciences Strengthens Global Intellectual Property PortfolioFebruary 22, 2024 | globenewswire.comProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceJanuary 22, 2024 | finance.yahoo.comProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineJanuary 3, 2024 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership TransitionJanuary 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)January 3, 2024 | markets.businessinsider.comProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive OfficerJanuary 3, 2024 | finance.yahoo.comProMIS Neurosciences, Inc. Announces Leadership TransitionNovember 14, 2023 | msn.comProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14September 6, 2023 | finance.yahoo.comProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 22, 2023 | msn.comProMIS Neurosciences scales 31% on $20.4M private placementAugust 21, 2023 | finance.yahoo.comProMIS Neurosciences Announces $20.4 Million Private Placement FinancingJuly 27, 2023 | marketbeat.comTrading was temporarily halted for "PMN" at 09:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "PMN" at 09:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "PMN" at 09:07 AM with a stated reason of "LULD pause."May 15, 2023 | finance.yahoo.comProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsMay 6, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Friday (PMN)April 27, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Thursday (PMN)April 25, 2023 | finance.yahoo.comData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s DiseaseApril 24, 2023 | finance.yahoo.comProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual MeetingApril 19, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Tuesday (PMN)April 18, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Monday (PMN)April 15, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Friday (PMN)April 10, 2023 | proactiveinvestors.comProMIS Neurosciences submits IND application for Alzheimer's treatmentSeptember 28, 2022 | marketbeat.comTrading was temporarily halted for "PMN" at 09:09 AM with a stated reason of "LULD pause."July 13, 2022 | marketbeat.comTrading was temporarily halted for "PMN" at 10:07 AM with a stated reason of "LULD pause." Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s PRIME is Set to Shock the World (Ad)Must-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing. Click here for the full story… PMN Media Mentions By Week PMN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMN News Sentiment▼0.890.49▲Average Medical News Sentiment PMN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMN Articles This Week▼40▲PMN Articles Average Week Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Marker Therapeutics News Sensei Biotherapeutics News Cara Therapeutics News Lexaria Bioscience News Xilio Therapeutics News Spruce Biosciences News Fortress Biotech News BriaCell Therapeutics News NRx Pharmaceuticals News Unicycive Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.